News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Perle Bioscience Aims to Cure Diabetes With Help From BlazeFund


9/27/2013 9:42:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON, Sept. 26, 2013 /PRNewswire/ -- 11-year-old Type 1 diabetes patient, Louis Cocco, conveyed statistics to a Washington, D.C. group about the impacts of diabetes in America:

  • 26 million patients.
  • 284,000 deaths last year.
  • Another diagnosis every 17 seconds.
  • Leading cause of amputations, blindness and kidney disease.
  • $245 Billion for patient care in 2012.

Finally, Louis turned towards Dr. Claresa Levetan, his endocrinologist, saying, "These group of doctors will get me off insulin before I am a grownup."

Dr. Irl Hirsch, editor-in-chief of the ADA Journal Clinical Diabetes, considers Dr. Levetan, an internationally recognized leader in diabetes research, as "the most creative physician I have ever met". She was co-founder and lead inventor of CureDM, whose IP portfolio was licensed to Sanofi in 2010 for payments potentially valued at $335M.

Her newest venture, Perle Bioscience (www.PerleBioscience.com), is "revolutionary and provides proprietary therapeutic treatment for diabetes." Perle looks to raise $2M in capital, representing 25% equity.

Nearly 10% of healthcare and 40% of Medicare spending goes towards diabetics. "Our innovative treatment focuses on fostering insulin independence; it will be a huge societal benefit by managing healthcare costs," states Dr. Levetan, adding, "Perle is making a paradigm shift in the treatment of diabetes; we chose BlazeFund because they specialize in life-sciences and are making a paradigm shift in accessing capital."

Aaron Sanders, founder and CEO of BlazeFund, adds, "BlazeFund provides the investment community with access to innovative ventures. We are proud to be working with Perle BioScience."

Sanders believes that BlazeFund enables entrepreneurs to raise capital and exercise greater control over terms whereas for investors, "A benefit of entering into early stage investments is the potential to capture greater capital appreciation."

BlazeFund is an equity crowdfunding company. BlazeFund's platform offers unique patent-pending features: connecting the crowd and institutions simultaneously to entrepreneurs and reducing investor risk via a two-step investment mechanism. BlazeFund works with entrepreneurs who have significant stakes of their own and university professors with unique business models, innovative technology, products and services, and commercially feasible ventures that can potentially deliver above-average risk-adjusted returns.

BlazeFund makes securing capital and investing in start-ups more transparent and efficient. We invite you to visit our portal and register to learn more. There are no fees or minimums for reviewing opportunities or investing.

SOURCE BlazeFund



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES